Natco Pharma share news, announcements and annual reports
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹787.55down ₹5.45 (0.69%)BSE ₹787.75
Share price at the NSE close on 29 Oct 2026. Previous close ₹793.00.
29 Oct: open ₹793.00, high ₹799.45, low ₹785.90
52-week range of traded prices to 29 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Next results date: the board meets on 13 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,449 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,27,66353.4% delivered
Natco Pharma disputes and clarifications
21 filed, newest first.
Jul 2026
14 Jul · Legal
May 2026
14 May · Legal
Feb 2025
21 Feb · Legal
Jan 2025
Aug 2021
20 Aug · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to announcement dated 20-Aug-2021, regarding its press release dated August 20, 2021. On basis of above the Company is required to clarify following: 1. Expected financial implications, if any, due to compensation, penalty etc;2. Quantum of claims, if anyThe response of the Company is awaited.
Jul 2021
8 Jul · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to announcement dated 07-Jul-2021, regarding a press release dated July 07, 2021, titled "legal update".On basis of above the Company is required to clarify following:1. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation;2. Expected financial implications, if any, due to compensation, penalty etc;3. Quantum of claims, if any.The response of the Company is awaited.
Feb 2020
14 Feb · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to announcement dated 12-Feb-2020, regarding Board of Directors at its meeting held on February 12, 2020. On basis of above the Company is required to clarify following: 1. Brief profile in case of appointment of M/s. Grant Thornton India LLP. The response of the Company is awaited.
Aug 2019
22 Aug · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to announcement dated 09-Aug-2019, regarding investments approved by the Board. On basis of above the Company is required to clarify following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).2. Percentage of shareholding / control acquired and / or number of shares acquired;3. Nature of consideration - whether cash consideration or share swap and details of the same;4. Cost of acquisition or the price at which the shares are acquired;5. Indicative time period for completion of the acquisition;6. Brief details of any governmental or regulatory approvals required for the acquisition;7. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);8. Industry to which the entity being acquired belongs;9. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";10. Name of the target entity, details in brief such as size, turnover etc;The response of the Company is awaited.
May 2018
24 May · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Feb 2018
7 Feb · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated limited review report not submitted. The response of the Company is awaited.
Dec 2014
17 Dec · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to an announcement submitted to the Exchange dated December 16, 2014 informing that the committee of Directors at a meeting held on December 16, 2014 allotted 1,61,775 equity shares of Rs.10/- each at a premium of Rs.1190/- per share on preferential basis other than cash to the promoters of Natco Organics Limited. On basis of above the Company is required to clarify following: i. Issue period; ii. Names of the investors and of these, which are promoters or promoter group entities, iii. Post allotment of securities: - outcome of the subscription, number of investors. The response of the Company is awaited.
Nov 2014
Oct 2013
11 Oct · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Natco Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Natco Pharma Limited has vide its letter inter-alia stated, "We do not have information as to the reasons thereof."
Jan 2013
24 Jan · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Natco Pharma Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Natco Pharma Limited has vide its letter inter-alia stated, "We have also noted the recent increase in the volume of our share trading but we do not have any information as to the reasons thereof."